9/25/2020 | SP | New Issue: UBS prices $715,000 trigger phoenix autocallables linked to iShares Nasdaq Biotech
|
8/21/2020 | SP | New Issue: UBS prices $750,000 trigger phoenix autocallables linked to iShares Nasdaq Biotech
|
8/10/2020 | SP | New Issue: UBS prices $250,000 return optimization securities on iShares Nasdaq Biotech
|
8/10/2020 | SP | New Issue: UBS prices $275,000 return optimization securities on iShares Nasdaq Biotech
|
6/22/2020 | SP | New Issue: UBS prices $225,000 airbag return optimization securities linked to Nasdaq Biotech ETF
|
10/23/2019 | SP | New Issue: BofA prices $2.33 million contingent income autocallable yield notes on two ETFs
|
7/8/2019 | SP | New Issue: RBC prices $8.59 million PLUS on basket of two indexes, five funds
|
5/16/2019 | SP | Citigroup plans contingent coupon autocallables tied to two ETFs
|
5/10/2019 | SP | New Issue: Citigroup prices $1.33 million contingent coupon autocallables linked to ETFs
|
5/3/2019 | SP | Credit Suisse eyes contingent coupon autocalls due 2022 on three ETFs
|
1/7/2019 | SP | New Issue: RBC prices $8.02 million PLUS on basket of two indexes, six funds
|
6/12/2018 | SP | New Issue: JPMorgan prices $1.28 million three-year review notes tied to biotech ETF
|
3/1/2018 | SP | New Issue: Barclays prices $1 million 14.5% rate phoenix autocalls tied to funds
|
8/23/2017 | SPSW | Despite selloff, volatility is still too low to boost coupons, raise caps, sellsiders say
|
8/22/2017 | SP | New Issue: Barclays prices $9.18 million phoenix autocallables tied to three funds
|
6/27/2017 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to iShares Nasdaq Biotech
|
6/22/2017 | SP | New Issue: HSBC prices $13.54 million autocallable contingent income barrier notes on stocks
|
5/18/2017 | SP | Market Commentary: BMO’s series of fixed-interest autocallables tied to ETFs raise the call threshold
|
5/4/2017 | SP | New Issue: Barclays prices $12.31 million phoenix autocallables on three funds
|
3/29/2017 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to iShares Nasdaq Biotech
|
1/10/2017 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq Biotech
|
1/9/2017 | SP | New Issue: UBS prices $134,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq Biotech
|
1/6/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq Biotech
|
1/5/2017 | SP | Credit Suisse plans high/low coupon autocallables tied to two funds
|
1/4/2017 | SP | New Issue: RBC prices $7.31 million PLUS due 2018 linked to basket
|
12/20/2016 | SP | New Issue: Barclays prices $7.79 million of phoenix autocallables on three funds
|
12/16/2016 | SP | New Issue: UBS prices $192,000 trigger phoenix autocallables linked to biotech ETF
|
12/15/2016 | SP | New Issue: UBS prices $400,000 trigger phoenix autocallables linked to biotech ETF
|
12/14/2016 | SP | RBC plans to price PLUS due June 2017 tied to index, ETF basket
|
12/9/2016 | SP | New Issue: UBS prices $170,000 trigger phoenix autocallables linked to biotech ETF
|
12/9/2016 | SP | New Issue: UBS prices $232,500 trigger phoenix autocallables linked to biotech ETF
|
11/3/2016 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to biotech ETF
|
11/3/2016 | SP | New Issue: UBS prices $219,000 trigger phoenix autocallables linked to biotech ETF
|
10/24/2016 | SP | New Issue: UBS prices $175,000 return optimization securities on iShares Nasdaq Biotech
|
7/22/2016 | SP | New Issue: UBS prices $110,000 return optimization securities on biotech ETF
|
6/8/2016 | SP | RBC plans trigger phoenix autocallable notes on worst of three ETFs
|
11/12/2015 | SP | New Issue: UBS prices $527,750 contingent absolute return autocallables linked to biotech ETF
|
9/8/2015 | SP | Market Commentary: Bank of Montreal plans three autocallables with high yield, American barrier, higher call strike
|
8/20/2015 | SP | New Issue: UBS prices $100,000 trigger autocallables linked to iShares Nasdaq Biotechnology
|
7/28/2015 | SP | New Issue: UBS prices $312,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq
|
7/28/2015 | SP | New Issue: UBS prices $315,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq
|
7/27/2015 | SP | New Issue: UBS prices $170,000 trigger autocallables linked to iShares Nasdaq Biotechnology
|
7/24/2015 | SP | New Issue: UBS prices $151,700 trigger autocallables linked to iShares Nasdaq Biotechnology ETF
|
7/8/2015 | SP | New Issue: UBS prices $315,000 trigger autocallables linked to iShares Nasdaq Biotechnology ETF
|
7/2/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq
|
6/4/2015 | SP | New Issue: UBS prices $2.23 million trigger autocallables linked to iShares Nasdaq
|
4/27/2015 | SP | New Issue: UBS prices $250,000 trigger autocallables linked to iShares Nasdaq
|
3/10/2015 | SP | New Issue: UBS prices $1.16 million trigger autocallables linked to iShares Nasdaq
|
1/27/2015 | SP | New Issue: UBS prices $130,000 contingent absolute return autocallable optimization securities linked to iShares Nasdaq
|
1/22/2015 | SP | New Issue: UBS prices $204,000 contingent absolute return autocallable optimization securities linked to iShares Nasdaq
|
1/6/2015 | SP | Market Commentary: UBS’ autocallables tied to biotech fund aimed at income investors with equity risk tolerance
|
1/6/2015 | SP | New Issue: UBS prices $375,000 trigger phoenix autocallable optimization securities linked to iShares Nasdaq
|
1/5/2015 | SP | UBS plans trigger autocallable optimization securities on biotech fund
|
7/23/2014 | SP | UBS plans trigger autocallable optimization securities on biotech fund
|